Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics

Drug repurposing (also known as drug repositioning, drug reprofiling, indication expansion or indication shift) involves establishing new medical uses for already known drugs, including approved, d...

[1]  W. Gutteridge,et al.  Trypanosoma cruzi: possible control of parasite transmission by blood transfusion using amphiphilic cationic drugs. , 1985, Experimental parasitology.

[2]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[3]  A. Talevi,et al.  Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake , 2018, Front. Cell. Infect. Microbiol..

[4]  Michel Quere,et al.  Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Ayfer Ali,et al.  The Major Role of Clinicians in the Discovery of Off‐Label Drug Therapies , 2006, Pharmacotherapy.

[6]  Alan Talevi,et al.  Drug repositioning: current approaches and their implications in the precision medicine era , 2018 .

[7]  M. Pollastri.  Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon. , 2017, Trends in parasitology.

[8]  V. Avery,et al.  Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes , 2015, International journal for parasitology. Drugs and drug resistance.

[9]  Leonardo L. G. Ferreira,et al.  Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. , 2016, Drug discovery today.

[10]  Tudor I Oprea,et al.  Computational and Practical Aspects of Drug Repositioning. , 2015, Assay and drug development technologies.

[11]  Therapeutic Drug Repurposing, Repositioning and Rescue , 2022 .

[12]  Alasdair Breckenridge,et al.  Overcoming the legal and regulatory barriers to drug repurposing , 2018, Nature Reviews Drug Discovery.

[13]  Richard A. Moore,et al.  Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Ritchie,et al.  Methods of integrating data to uncover genotype–phenotype interactions , 2015, Nature Reviews Genetics.

[15]  Malorye Allison,et al.  NCATS launches drug repurposing program , 2012, Nature Biotechnology.

[16]  I D Kerr,et al.  Two approaches to discovering and developing new drugs for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[17]  Michelle R. Arkin,et al.  Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[18]  Wei Zheng,et al.  Drug combination therapy increases successful drug repositioning. , 2016, Drug discovery today.

[19]  Pablo H. Palestro,et al.  Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. , 2015, European journal of medicinal chemistry.

[20]  Timothy X. Witkowski.  Intellectual property and other legal aspects of drug repurposing , 2011 .

[21]  J. Palacios,et al.  Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH , 2017, Clinical and Translational Oncology.

[22]  Minna Allarakhia,et al.  Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases , 2013, Drug design, development and therapy.

[23]  F. Buckner,et al.  Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi , 2014, PLoS neglected tropical diseases.

[24]  W. Gutteridge,et al.  A novel series of chemical structures active in vitro against the trypomastigote form of Trypanosoma cruzi. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.